Nombre del producto:N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide
IUPAC Name:N-[5-iodo-7-(4-methylbenzenesulfonyl)-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-2-yl]-2,2-dimethylpropanamide
| Unidad de embalaje | Stock disponible | Precio($) | Cantidad |
|---|---|---|---|
| CM557880-1g | in stock | țȬ |
|
| CM557880-5g | in stock | ǜǶț |
|
|
|||
| Product Overview |
N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide, also known as KIRA6, is a small molecule inhibitor that targets the E3 ubiquitin ligase, IRE1α. IRE1α is a stress sensor that plays a crucial role in the unfolded protein response (UPR) pathway. The UPR pathway is activated when the endoplasmic reticulum (ER) is under stress and leads to the degradation of misfolded proteins. IRE1α is a promising therapeutic target for various diseases, including cancer, inflammation, and neurodegenerative disorders. |
| Synthesis and Application |
The synthesis of N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide involves a multi-step process starting from commercially available starting materials. The synthesis route involves the use of various reagents and solvents under controlled conditions. The final product is obtained after purification using column chromatography. The synthesis of N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide has been reported in several scientific publications, including the Journal of Medicinal Chemistry. N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide has been extensively studied in various preclinical models, including cell lines and animal models. The compound has shown promising results in inhibiting IRE1α activity and reducing ER stress in cancer cells. N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide has also been shown to have anti-inflammatory effects in preclinical models of inflammatory bowel disease and neuroprotective effects in models of neurodegenerative diseases. |
| Future Directions |
There are several future directions for the study of N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide. One potential application is in the treatment of cancer. N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide has shown promising results in preclinical models of various types of cancer, including breast, lung, and pancreatic cancer. Clinical trials are needed to evaluate the safety and efficacy of N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide in cancer patients. Another potential application is in the treatment of neurodegenerative diseases. N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide has neuroprotective effects in preclinical models of Alzheimer's and Parkinson's disease, and further research is needed to evaluate its potential as a therapeutic agent. Finally, N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide may have applications in the treatment of inflammatory diseases, including inflammatory bowel disease and rheumatoid arthritis. Clinical trials are needed to evaluate the safety and efficacy of N-(5-iodo-4-oxo-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide in these conditions. |
Buscar 
+86 21 5895 0110 
